Capital Raise of $182 Million Confirms Eavor as the Leader in Scalable Geothermal 26-10-2023, 03:30

nCino Reports Fourth Quarter and Fiscal Year 2024 Financial Results 27-03-2024, 03:05

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00